Trackins (Trk-Targeting Drugs): A Novel Therapy for Different Diseases.

Many routes may lead to the transition from a healthy to a diseased phenotype. However, there are not so many routes to travel in the opposite direction; that is, therapy for different diseases. The following pressing question thus remains: what are the pathogenic routes and how can be they counteracted for therapeutic purposes? Human cells contain >500 protein kinases and nearly 200 protein phosphatases, acting on thousands of proteins, including cell growth factors.

Xanthates: Metabolism by Flavoprotein-Containing Monooxygenases and Antimycobacterial Activity.

Ethionamide (ETH) plays a central role in the treatment of tuberculosis in patients resistant to the first-line drugs. The ETH, thioamide, and thiourea class of antituberculosis agents are prodrugs that are oxidatively converted to their active -oxides by the mycobacterial flavin-dependent monooxygenase (EtaA) of , thus initiating the chain of reactions that result in inhibition of mycolic acid biosynthesis and cell lysis. As part of a search for new lead candidates, we report here that several xanthates are oxidized by purified EtaA to -oxide metabolites (perxanthates), which are implicated in the antimycobacterial activity of these compounds.

Xanthates As Useful Probes for Testing the Active Sites of Cytochromes P450 4A11 and 2E1.

Xanthates (alkyl or aryl derivatives of dithiocarbonic acid) have been shown to be selective mechanism-based inactivators of cytochromes P450 2B1/2B6 and 2E1 due to covalent binding of a reactive intermediate to apoprotein after double hydrogen abstraction at α-carbon atom, suggesting interaction of the xanthate dithiocarbonic head with the enzyme heme. The structures of xanthates with a long alkyl chain are similar to the fatty acids. Saturated fatty acids (FA) such as lauric acid (LA), are metabolized by different cytochrome P450 isoforms to ω- and (ω-1)-hydroxy products, in humans done by CYP4A11 and CYP2E1, respectively.

Galanthamine production by Leucojum aestivum cultures in vitro.

The results described in these studies proved that the successful in vitro bioproduction of galanthamine from L. aestivum shoot-clumps required mainly the selection of in vitro clones with a genetically determined high ability to produce the desired alkaloids, although the expression of this ability could be additionally influenced by diverse exterior factors, such as some components of the nutrient medium, or the cultivation conditions of the ambience. Tissue differentiation was also of great importance for the biosynthetic capacity of the cultures.